Abstract
Orgaran (danaparoid sodium injection) is a novel antithrombotic agent. Early studies suggest that this compound may be beneficial in preventing deep vein thrombosis in predisposed patients. This multicenter, randomized, assessor blinded, clinical trial compared subcutaneous danaparoid with warfarin for the prevention of deep vein thrombosis in patients undergoing hip replacement surgery. Bilateral venography was used to detect thrombi. Patients also underwent follow-up examinations 1, 2, and 3 months after discontinuation of the study to determine the after effects of treatment. Nearly 27% of patients who received warfarin and 14.6% of patients who received danaparoid developed deep vein thrombosis, a risk reduction of 46%. The absolute difference in the incidence of deep vein thrombosis was 12.3% in favor of danaparoid. The incidence of venographically documented proximal deep vein thrombosis was 1.5% for danaparoid and 4.1% for warfarin. These results demonstrate that danaparoid is more effective than warfarin in preventing deep vein thrombosis following hip replacement surgery. The preoperative administration of danaparoid does not increase surgical blood loss compared with warfarin.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1123-1128 |
| Number of pages | 6 |
| Journal | Orthopedics |
| Volume | 21 |
| Issue number | 10 |
| State | Published - Oct 1998 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Surgery
- Orthopedics and Sports Medicine
Cite this
A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement. / Comp, Philip C.; Voegeli, Thomas; McCutchen, John W.; Skoutakis, Vasilios A.; Trowbridge, Arthur; Overdyke, William L.; Boynton, Lynn; Wise, Gregory; Kwaan, Hau; Geckler, Ronald W.; Kalafer, Michael; White, Richard H; Lyons, Roger M.; White, Paul F.
In: Orthopedics, Vol. 21, No. 10, 10.1998, p. 1123-1128.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement
AU - Comp, Philip C.
AU - Voegeli, Thomas
AU - McCutchen, John W.
AU - Skoutakis, Vasilios A.
AU - Trowbridge, Arthur
AU - Overdyke, William L.
AU - Boynton, Lynn
AU - Wise, Gregory
AU - Kwaan, Hau
AU - Geckler, Ronald W.
AU - Kalafer, Michael
AU - White, Richard H
AU - Lyons, Roger M.
AU - White, Paul F.
PY - 1998/10
Y1 - 1998/10
N2 - Orgaran (danaparoid sodium injection) is a novel antithrombotic agent. Early studies suggest that this compound may be beneficial in preventing deep vein thrombosis in predisposed patients. This multicenter, randomized, assessor blinded, clinical trial compared subcutaneous danaparoid with warfarin for the prevention of deep vein thrombosis in patients undergoing hip replacement surgery. Bilateral venography was used to detect thrombi. Patients also underwent follow-up examinations 1, 2, and 3 months after discontinuation of the study to determine the after effects of treatment. Nearly 27% of patients who received warfarin and 14.6% of patients who received danaparoid developed deep vein thrombosis, a risk reduction of 46%. The absolute difference in the incidence of deep vein thrombosis was 12.3% in favor of danaparoid. The incidence of venographically documented proximal deep vein thrombosis was 1.5% for danaparoid and 4.1% for warfarin. These results demonstrate that danaparoid is more effective than warfarin in preventing deep vein thrombosis following hip replacement surgery. The preoperative administration of danaparoid does not increase surgical blood loss compared with warfarin.
AB - Orgaran (danaparoid sodium injection) is a novel antithrombotic agent. Early studies suggest that this compound may be beneficial in preventing deep vein thrombosis in predisposed patients. This multicenter, randomized, assessor blinded, clinical trial compared subcutaneous danaparoid with warfarin for the prevention of deep vein thrombosis in patients undergoing hip replacement surgery. Bilateral venography was used to detect thrombi. Patients also underwent follow-up examinations 1, 2, and 3 months after discontinuation of the study to determine the after effects of treatment. Nearly 27% of patients who received warfarin and 14.6% of patients who received danaparoid developed deep vein thrombosis, a risk reduction of 46%. The absolute difference in the incidence of deep vein thrombosis was 12.3% in favor of danaparoid. The incidence of venographically documented proximal deep vein thrombosis was 1.5% for danaparoid and 4.1% for warfarin. These results demonstrate that danaparoid is more effective than warfarin in preventing deep vein thrombosis following hip replacement surgery. The preoperative administration of danaparoid does not increase surgical blood loss compared with warfarin.
UR - http://www.scopus.com/inward/record.url?scp=7344223314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7344223314&partnerID=8YFLogxK
M3 - Article
C2 - 9801236
AN - SCOPUS:7344223314
VL - 21
SP - 1123
EP - 1128
JO - Orthopedics
JF - Orthopedics
SN - 0147-7447
IS - 10
ER -